You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Breaking news on Precision Oncology business, policy & funding.
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.
The approval from China's National Medical Products Administration expands access to the drug in a country with a significant lung cancer burden.
The company's pipeline includes a KIT inhibitor that will move into clinical studies this year and an EGFR inhibitor in preclinical studies.